Patents by Inventor Hector F. DeLuca

Hector F. DeLuca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11697635
    Abstract: Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 from the solution.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 11, 2023
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. Deluca, Margaret Clagett-Dame, Lori Plum, Agnieszka Flores, James Thoden, Hazel Holden
  • Patent number: 11266664
    Abstract: A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 8, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Steven Marling, Lori A. Plum, Yanping F. Wang
  • Patent number: 11260241
    Abstract: A method and computer program product for suppressing the symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with a pre-determined dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 1, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. Deluca, Bryan R. Becklund
  • Patent number: 10780295
    Abstract: Methods and devices for suppressing clinical symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with an effective dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: September 22, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Yanping Wang, Steven Marling
  • Publication number: 20200281947
    Abstract: An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed.
    Type: Application
    Filed: May 19, 2020
    Publication date: September 10, 2020
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Publication number: 20200262773
    Abstract: Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro-1?,24,25-trihydroxy-19-nor-vitamin D3 from the solution.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 20, 2020
    Inventors: Hector F. DELUCA, Margaret CLAGETT-DAME, Lori PLUM, Agnieszka FLORES, James THODEN, Hazel HOLDEN
  • Publication number: 20200061084
    Abstract: The invention relates to using 2-methylene-19-nor-(20S)-1?,25-(OH)2D3 (2MD) or 2?-methyl-19-nor-(20S)-1?,25-(OH)2D3 (2MD) to prevent nephrotoxicity and/or fibrosis in a patient, preferably without causing hypercalcemia in the patient.
    Type: Application
    Filed: October 3, 2019
    Publication date: February 27, 2020
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Hans W. Sollinger, Bianca Raquel Tomasini-Johansson, Lori A. Plum, Debra Hullett
  • Publication number: 20190381335
    Abstract: A method and computer program product for suppressing the symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with a pre-determined dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject.
    Type: Application
    Filed: September 14, 2018
    Publication date: December 19, 2019
    Inventors: Hector F. Deluca, Bryan R. Becklund
  • Publication number: 20190381075
    Abstract: A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.
    Type: Application
    Filed: August 23, 2019
    Publication date: December 19, 2019
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Steven Marling, Lori A. Plum, Yanping F. Wang
  • Patent number: 10494337
    Abstract: Disclosed are 1?,25-dihydroxy-24,24-difluoro-2-methylene-19-nor-vitamin D analogs and their pharmaceutical uses. These new vitamin D analogs are 19-nor-vitamin D analogs having two fluorine atom substitutions at the 24 position (C-24) in the side chain and optionally having a 2-methylene substituent.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: December 3, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Agnieszka Flores, Lori A. Plum, Hazel Holden, James Thoden
  • Patent number: 10479764
    Abstract: This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1?-hydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows low activity in vivo on bone calcium mobilization, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: November 19, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Rafal Barycki
  • Patent number: 10434110
    Abstract: A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 8, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Hector F. DeLuca, Steven Marling, Lori A. Plum, Yanping F. Wang
  • Patent number: 10369161
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism and/or to treat and/or prevent the symptoms of primary hyperparathyroidism in as subject having or at risk for developing primary hyperparathyroidism, preferably without inducing hypercalcemia in the patient.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: August 6, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Publication number: 20190009104
    Abstract: A method and computer program product for suppressing the symptoms of multiple sclerosis (MS) by irradiating a subject exhibiting the symptoms with a pre-determined dose of UV-containing light from a light source and detecting a suppression of the clinical symptoms of MS. In particular, the detected suppression of the clinical symptoms is disassociated from the vitamin D production within the subject.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 10, 2019
    Inventors: Hector F. Deluca, Bryan R. Becklund
  • Patent number: 10105375
    Abstract: Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 23, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum
  • Patent number: 10046000
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Publication number: 20180055856
    Abstract: Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Application
    Filed: August 1, 2017
    Publication date: March 1, 2018
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum
  • Publication number: 20180015107
    Abstract: A method of treating an MS patient with homosalate, octyl salicylate, or a combination is disclosed.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 18, 2018
    Inventors: Hector F. DeLuca, Steven Marling, Lori A. Plum, Yanping F. Wang
  • Publication number: 20170326159
    Abstract: Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 16, 2017
    Inventors: Margaret Clagett-Dame, Hector F. DeLuca, Nirca J. Nieves, Lori A. Plum, Mary E. Kaiser
  • Patent number: 9814736
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 14, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame